OBJECTIVES: To characterize real-world treatment patterns among front-line patients with glioblastoma in Germany, France, Italy, UK, and Spain (EU-5).  METHODS: This study used the oncologist-surveyed data from the IMS LifeLink™ Oncology Analyzer database. Front-line patients aged ≥ 20 years and diagnosed with glioblastoma during 2012 to 2014 in the EU-5 countries were included. Patient demographics, comorbidities, therapy type, treatment initiator, and concomitant medications were descriptively examined across the EU-5 and by individual country.  RESULTS: A total of 64,932 patients from Germany (24,577), France (12,574), Italy (11,676), UK (8,427), and Spain (7,698) were included.  The majority were male (64%, except Germany was 50%), >56 years (70%), and had chemo-radiation (91%). Comorbidities were similar across countries, except COPD (5%, whereas Spain was 19%) and Cardiac Dysfunction (4%, whereas Germany was 21%). Except in the UK, temozolomide was used, on average, for 82% of front-line patients with treatment being initiated by a radiologist (58%) or medical oncologist (23%). In the UK, temozolomide was used for 65% of front-line patients and was initiated by a radiologist 90% of the time. Surgical procedures including Excision of Lesion, Craniotomy, and Lobectomy were performed, on average, in 67% of patients, except in France (44%).  However, French patients were more likely to have a Burr Hole Biopsy (43%) versus the other 4 countries (average of 20%).  Frequently used concomitant medications were corticosteroids (3-fold variation across EU-5), anti-emetics (5-fold variation), and gastrointestinal medications (on average 20%). CONCLUSIONS: The common front-line treatment for glioblastoma was found to be surgery followed by temozolomide chemotherapy, consistent with guidelines. However, there was some variation across countries with regards to the type of surgery, comorbidities, chemotherapy initiator, and concomitant medications. Further study is needed to comprehensively characterize glioblastoma treatment patterns in the EU-5.